BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 9491625)

  • 1. [Rejection antigens of tumors and specific immunotherapy of cancer].
    Boon T; Lucas S
    Bull Mem Acad R Med Belg; 1996; 151(12):469-79. PubMed ID: 9491625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Melanoma antigen genes(MAGE) and malignant tumors].
    Xu JZ; Lin S
    Ai Zheng; 2003 Sep; 22(9):1001-4. PubMed ID: 12969539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a MAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-B*5701 tumors.
    Corbière V; Nicolay H; Russo V; Stroobant V; Brichard V; Boon T; van der Bruggen P
    Tissue Antigens; 2004 May; 63(5):453-7. PubMed ID: 15104676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma.
    Huang LQ; Brasseur F; Serrano A; De Plaen E; van der Bruggen P; Boon T; Van Pel A
    J Immunol; 1999 Jun; 162(11):6849-54. PubMed ID: 10352307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide.
    Nishiyama T; Tachibana M; Horiguchi Y; Nakamura K; Ikeda Y; Takesako K; Murai M
    Clin Cancer Res; 2001 Jan; 7(1):23-31. PubMed ID: 11205913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential of melanoma antigen expression in cancer therapy.
    Gillespie AM; Coleman RE
    Cancer Treat Rev; 1999 Aug; 25(4):219-27. PubMed ID: 10448130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes.
    Schultz ES; Lethé B; Cambiaso CL; Van Snick J; Chaux P; Corthals J; Heirman C; Thielemans K; Boon T; van der Bruggen P
    Cancer Res; 2000 Nov; 60(22):6272-5. PubMed ID: 11103782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.
    Chaux P; Luiten R; Demotte N; Vantomme V; Stroobant V; Traversari C; Russo V; Schultz E; Cornelis GR; Boon T; van der Bruggen P
    J Immunol; 1999 Sep; 163(5):2928-36. PubMed ID: 10453041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity.
    Dutoit V; Rubio-Godoy V; Dietrich PY; Quiqueres AL; Schnuriger V; Rimoldi D; Liénard D; Speiser D; Guillaume P; Batard P; Cerottini JC; Romero P; Valmori D
    Cancer Res; 2001 Aug; 61(15):5850-6. PubMed ID: 11479225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Identification of cancer antigens of relevance for specific cancer immunotherapy].
    van den Eynde B
    Bull Mem Acad R Med Belg; 2001; 156(10-12):548-55. PubMed ID: 12371273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The melanoma antigen genes--any clues to their functions in normal tissues?
    Ohman Forslund K; Nordqvist K
    Exp Cell Res; 2001 May; 265(2):185-94. PubMed ID: 11302683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides.
    Zhang XM; Zhang YF; Huang Y; Qu P; Ma B; Si SY; Li ZS; Li WX; Li X; Ge W; Hu PZ; Sui YF
    Oncol Rep; 2008 Jul; 20(1):245-52. PubMed ID: 18575744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression patterns of cancer testis antigens in testicular germ cell tumors and adjacent testicular tissue.
    Yuasa T; Okamoto K; Kawakami T; Mishina M; Ogawa O; Okada Y
    J Urol; 2001 May; 165(5):1790-4. PubMed ID: 11342977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new MAGE gene with ubiquitous expression does not code for known MAGE antigens recognized by T cells.
    Lucas S; Brasseur F; Boon T
    Cancer Res; 1999 Aug; 59(16):4100-3. PubMed ID: 10463614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspectives for immunization of HLA-A1 patients carrying a malignant melanoma expressing gene MAGE-1.
    Marchand M; Brasseur F; van der Bruggen P; Coulie P; Boon T
    Dermatology; 1993; 186(4):278-80. PubMed ID: 8513199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genes coding for tumor rejection antigens: perspectives for specific immunotherapy.
    Boon T; Coulie P; Marchand M; Weynants P; Wölfel T; Brichard V
    Important Adv Oncol; 1994; ():53-69. PubMed ID: 8206495
    [No Abstract]   [Full Text] [Related]  

  • 17. Genes coding for melanoma antigens recognised by cytolytic T lymphocytes.
    De Smet C; Lurquin C; De Plaen E; Brasseur F; Zarour H; De Backer O; Coulie PG; Boon T
    Eye (Lond); 1997; 11 ( Pt 2)():243-8. PubMed ID: 9349420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte.
    Lethé B; van der Bruggen P; Brasseur F; Boon T
    Melanoma Res; 1997 Aug; 7 Suppl 2():S83-8. PubMed ID: 9578421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes.
    Schiavetti F; Thonnard J; Colau D; Boon T; Coulie PG
    Cancer Res; 2002 Oct; 62(19):5510-6. PubMed ID: 12359761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression spectrum of melanoma antigen-encoding gene family members in colorectal carcinoma.
    Hasegawa H; Mori M; Haraguchi M; Ueo H; Sugimachi K; Akiyoshi T
    Arch Pathol Lab Med; 1998 Jun; 122(6):551-4. PubMed ID: 9625425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.